Trial site
Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbH
Buxtehude, 21614, GermanyNot linked to an institution yet
- 13running trials
- 11closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 23 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Completed11 trials
- Active, not recruiting10 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Sanofi4 trials
- Merck Sharp & Dohme LLC3 trials
- Bristol-Myers Squibb2 trials
- Novartis Pharmaceuticals2 trials
- AbbVie1 trial
- and 12 more
Running trials
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Eikon Therapeutics· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
2023-505739-12-01· Phase 3· Novartis Pharma AG· Source
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· Phase 3· LEO Pharma· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
NCT05694884· Phase 2· Aslan Pharmaceuticals Pte Ltd· Source
Active, not recruiting
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· Phase 3· Novartis Pharmaceuticals· Source
Terminated
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· Phase 2· Sanofi· Source
Active, not recruiting
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)
2022-502354-14-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922· Phase 2/3· Bristol-Myers Squibb· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
NCT02362594· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error